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ABSTRACT The distribution of N-acetyltransferase 2 gene (NAT2) polymorphisms
varies considerably among different ethnic groups. Information on NAT2 single-
nucleotide polymorphisms in the South African population is limited. We investi-
gated NAT2 polymorphisms and their effect on isoniazid pharmacokinetics (PK) in
Zulu black HIV-infected South Africans in Durban, South Africa. HIV-infected par-
ticipants with culture-confirmed pulmonary tuberculosis (TB) were enrolled from
two unrelated studies. Participants with culture-confirmed pulmonary TB were
genotyped for the NAT2 polymorphisms 282CT, 341TC, 481CT, 857GA,
590GA, and 803AG using Life Technologies prevalidated TaqMan assays (Life
Technologies, Paisley, UK). Participants underwent sampling for determination of
plasma isoniazid and N-acetyl-isoniazid concentrations. Among the 120 patients,
63/120 (52.5%) were slow metabolizers (NAT2*5/*5), 43/120 (35.8%) had an inter-
mediate metabolism genotype (NAT2*5/12), and 12/120 (11.7%) had a rapid me-
tabolism genotype (NAT2*4/*11, NAT2*11/12, and NAT2*12/12). The NAT2 alleles
evaluated in this study were *4, *5C, *5D, *5E, *5J, *5K, *5KA, *5T, *11A, *12A/12C,
and *12M. NAT2*5 was the most frequent allele (70.4%), followed by NAT2*12
(27.9%). Fifty-eight of 60 participants in study 1 had PK results. The median area under
the concentration-time curve from 0 to infinity (AUC0–∞) was 5.53 (interquartile range
[IQR], 3.63 to 9.12 g h/ml), and the maximum concentration (Cmax) was 1.47 g/ml
(IQR, 1.14 to 1.89 g/ml). Thirty-four of 40 participants in study 2 had both PK results
and NAT2 genotyping results. The median AUC0–∞ was 10.76 g·h/ml (IQR, 8.24 to 28.96
g·h/ml), and the Cmax was 3.14g/ml (IQR, 2.39 to 4.34 g/ml). Individual polymor-
phisms were not equally distributed, with some being represented in small numbers.
The genotype did not correlate with the phenotype, with those with a rapid acetylator
genotype showing higher AUC0–∞ values than those with a slow acetylator genotype,
but the difference was not significant (P 0.43). There was a high prevalence of slow
acetylator genotypes, followed by intermediate and then rapid acetylator genotypes.
The poor concordance between genotype and phenotype suggests that other factors or
genetic loci influence isoniazid metabolism, and these warrant further investigation in
this population.
KEYWORDS acetylation, N-acetyltransferase, isoniazid, tuberculosis, HIV,
pharmacokinetics, drug metabolism, pharmacogenetics
CitationMthiyane T, Millard J, Adamson J,
Balakrishna Y, Connolly C, Owen A, Rustomjee
R, Dheda K, McIlleron H, Pym AS. 2020.
N-Acetyltransferase 2 genotypes among Zulu-
speaking South Africans and isoniazid and
N-acetyl-isoniazid pharmacokinetics during
antituberculosis treatment. Antimicrob Agents
Chemother 64:e02376-19. https://doi.org/10
.1128/AAC.02376-19.
Copyright © 2020 Mthiyane et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Thuli Mthiyane,
thuli.mthiyane@mrc.ac.za.
Received 3 December 2019
Accepted 23 December 2019





April 2020 Volume 64 Issue 4 e02376-19 aac.asm.org 1Antimicrobial Agents and Chemotherapy
24 March 2020
Tuberculosis (TB) remains a leading cause of global morbidity and mortality, withapproximately 10 million cases and 1.5 million deaths occurring in 2018 (1). South
Africa is a high-TB-burden country, with an estimated 301,000 cases in 2018. The
so-called short-course treatment regimen recommended in international guidelines,
consisting of 6 months of rifampin and isoniazid (INH), supplemented by pyrazinamide
and ethambutol in the first 2 months, has remained largely unchanged for several
decades. While this regimen can achieve high relapse-free cure rates, a range of host
and mycobacterial factors can influence treatment outcomes. There is increasing
evidence that interindividual variability in the pharmacokinetics (PK) of drugs within
this regimen lead to heterogeneity in clinical outcomes (2, 3).
Pharmacogenomics (PG) describe one cause of PK variability due to polymorphisms
in drug-metabolizing enzymes (DME) and transporters. During anti-TB treatment, iso-
niazid is the paradigmatic case. Isoniazid is acetylated to its major metabolite, N-acetyl-
isoniazid (AcINH), by the action of hepatic N-acetyltransferase 2 (encoded by the NAT2
gene). AcINH is subsequently rapidly hydrolyzed to acetyl-hydrazine, which is also
acetylated to diacetyl-hydrazine, by the action of NAT2 (4). Accumulated acetyl-
hydrazine can be oxidized to form other, potentially hepatotoxic metabolites (4–6).
Moreover, the accumulated isoniazid can be metabolized by an alternative pathway, in
which it is first hydrolyzed to hydrazine, which has also been implicated in liver injury,
before acetylation to acetyl-hydrazine, which is, again, by NAT2 (4, 7). Hence, the activity
of NAT2 both dictates the metabolism of isoniazid and determines the availability of
potentially hepatoxic hydrazine and acetyl-hydrazine metabolites. Within the 870-bp
NAT2 gene, a number of low-activity single-nucleotide polymorphisms (SNPs) have
been characterized. The NAT2 genotype has been shown to determine the rate of
acetylation by NAT2 in several populations (8). Individuals homozygous for the wild-
type alleles are characterized as rapid acetylators (RAs), those homozygous for low-
activity SNPs are characterized as slow acetylators (SAs), and heterozygotes are char-
acterized as intermediate acetylators (IAs) (9–13). SAs have a higher incidence of side
effects, particularly drug-induced hepatitis, during anti-TB therapy, presumably due to
higher levels of hepatoxic metabolites (14–20). Among the first-line anti-TB drugs,
isoniazid has the greatest early bactericidal activity (EBA), and isoniazid PK parameters
have been associated with the rates of cure, sterilization, and acquired drug resistance
(3, 21–27). A link between rapid acetylation and an increased risk of poor treatment
outcomes has been reported (28, 29).
The NAT2 genotype is known to differ among ethnic groups, with approximately 40
to 70% of Caucasians, Indians, and African Americans but only about 10% of Asian
populations being characterized as SAs (30–42). The NAT2 genotype is not well char-
acterized in the communities where TB is most prevalent, particularly in sub-Saharan
Africa. South Africa has several black ethnic groups, and few have been studied (43–45).
Bach et al. characterized 40% of a Zulu population to be phenotypically slow acetylators,
but these findings have not been replicated or informed by genotypic analysis (44).
Moreover, South Africa has a high prevalence of individuals infected with HIV, and discor-
dant relationships between the NAT2 genotype and the isoniazid acetylator phenotype
have been described among individuals living with HIV in other settings (46, 47).
We therefore characterized the relationship between NAT2 genotype, isoniazid and
AcINH PK, and hepatotoxicity in a cohort of individuals with TB-HIV coinfection in
Durban, KwaZulu-Natal, South Africa.
RESULTS
Participant characteristics. One hundred twenty-two individuals living with HIV
and participating in two PK studies were included in the study. Eighty participants in
study 1 were included in the NAT2 genotyping analysis and 60 participants in study 1
were included in the PK analysis (with 58 individuals having both PK and genotype
data), while 40 participants in study 2 were included in the PK analysis and 40
participants in study 2 were included in NAT2 genotyping analysis (with 34 individuals
having both PK and genotype data). Key characteristics are outlined in Table 1.
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Participants in study 1 included 60 with pulmonary TB and HIV coinfection, 40 with CD4
counts of 200 cells/mm3, and 20 with CD4 counts of 200 cells/mm3, as well as 20
participants living with HIV and without TB (who contributed only genotype data). All
40 participants in study 2 had TB and HIV coinfection and had CD4 counts of 200 cells/
mm3 or below. In the combined studies, 66.7% of participants had CD4 counts of
200 cells/mm3 and 33.3% had CD4 counts of 200 cells/mm3. The median age was
33.1 years (interquartile range [IQR], 18 to 53 years). Only 15 (12.5%) patients had a
body mass index (BMI) of 18.86 kg/m2.
NAT2 genotype and deduced phenotype. One hundred twenty participants (80
from study 1 and 40 from study 2) were genotyped. The haplotype assignment and
deduced acetylator phenotype for each diplotype are shown in Table 2. Allele and
haplotype frequencies and deduced phenotypes are outlined in Tables 3 to 5. We
identified 12 different alleles in the population. The most common allelic group was
NAT2*5 (70.4%), followed by NAT2*12 (27.9%). In the NAT2*5 group, NAT2*5C (21.3%),
NAT2*5J (17.5%), NAT2*5D (14.6%), and NAT2*5K (10.4%) were the most common.
The NAT2*12 group was predominantly NAT2*12C. The proportions of individuals with
each of the deduced phenotypes was 11.7% rapid, 35.8% intermediate, and 52.5% slow
acetylators (Table 5).
Isoniazid and N-acetyl-isoniazid PK. As described above, to assess the sample
integrity for study 1, we compared the area under the concentration-time curve from
0 h to infinity (AUC0–∞) values from the current analysis with those previously reported
for the same samples analyzed in 2010. The median AUC0–∞ was 5.53 g·h/ml (IQR, 3.63
to 9.12 g·h/ml), when the samples were processed at the University of Cape Town
(UCT) in 2009, and 5.70 g·h/ml (IQR, 3.85 to 7.94 g·h/ml), when the samples were
processed at the Africa Health Research Institute (AHRI) laboratory in 2014, suggesting
that the integrity of the samples was maintained for isoniazid but could not be
confirmed for AcINH.
The participants in study 1 showed rapid absorption, with a median isoniazid time
to maximum concentration (Tmax) of 1 h (IQR, 1 to 2 h). Isoniazid exposure was variable
among individuals, with the median maximum concentration (Cmax) being 1.47 g/ml
(IQR, 1.14 to 1.85 g/ml) and the median AUC0–∞ being 5.53 g·h/ml (IQR, 3.63 to 9.12
g·h/ml) (Table 6). The median elimination half-life was relatively slow at 2.27 h (IQR,
1.69 to 3.56 h). We compared these isoniazid PK measures to published targets; 98.28%
(57/58) of the participants failed to attain the minimum 2-h plasma concentration
target of 3 g/ml (48). PK parameters by genotype are shown in Table 7. Unexpectedly,
the median half-life was the slowest, the apparent oral clearance was the lowest, and
AUC0–∞ was the highest among genotypically rapid acetylators, with the reverse being
true for genotypically slow acetylators, although none of these differences was statis-
tically significant. Similarly, there were no statistically significant differences by geno-
type for the AcINH Cmax, elimination half-life, or AUC0–∞. The median isoniazid and
AcINH time-concentration curves are given in Fig. 1, left.
TABLE 1 Demographic characteristics
Characteristic
Value for participants in:
Study 1 (n 80) Study 2 (n 40) Overall (n 120)
Demographics
Median (IQR) age (yr) 33 (18–48) 33.6 (24–53) 33.1 (18–53)
No. (%) of male participants 36 (45) 24 (60.0) 60 (50)
No. (%) of participants of Zulu ethnicity 80 (100) 40 (100) 120 (100)
Mean (SD) wt (kg) 58.7 (11.9) 58.9 (9.7) 58.7 (11.2)
Mean (SD) BMI 23.0 (5.2) 23.1 (3.9) 23.1 (4.8)
No. (%) of participants with BMI of 18.5 13 (16.3) 2 (5.0) 15 (12.5)
Median (range) CD4 count (no. of cells/mm3) 210.5 (10–500) 128 (61–199) 161 (10–500)
No. (%) of participants with CD4 count of 200 cells/mm3 40 (50) 40 (100) 80 (66.7)
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Absorption was rapid in the participants in study 2, with the median INH Tmax being
2 h. INH exposure was also variable among the individuals, with the median Cmax being
3.14 g/ml (IQR, 2.39 to 4.34 g/ml) and the median AUC0–∞ being 10.76 g·h/ml (IQR,
8.24 to 28.96 g·h/ml). The median elimination half-life was 2.62 (IQR, 2.26 to 4.07)
(Table 6). Again, we compared these INH PK measures to published PK targets; 47.5%
(19/40) of the participants failed to attain the minimum 2-h plasma concentration
target of 3 g/ml. PK parameters by genotype are shown in Table 8. For both isoniazid
and AcINH and across the PK parameters Cmax, AUC0–∞, and elimination half-life,
variability (both range and IQR) was increased among those genotyped as SAs. Again,
however, there were no statistically significant differences between these PK parame-
TABLE 2 NAT2 diplotypes and genotypes and deduced phenotype in the study group
Observed diplotypea No. of mutations NAT2 genotype Phenotype
–20000 1 5D/5K Slow
000020 1 12A/12A Rapid
001000 1 4/11A Rapid
001020 6 12A/12C Rapid
002010 2 11A/12C Rapid
002020 4 12C/12C Rapid
01–020 1 5C/12C Intermediate
010010 1 5D/12A Intermediate
010020 2 5C/12A Intermediate
010110 2 5E/12A Intermediate
011010 3 5D/12C Intermediate
011020 15 5C/12C Intermediate
011110 3 5E/12C Intermediate
0200-0 1 5C/5D Slow
020000 1 5D/5D Slow
020010 10 5C/5D Slow
020020 3 5C/5C Slow
020100 3 5D/5E Slow
020110 1 5C/5E Slow
110010 1 5K/12A Intermediate
110110 1 5K/12C Intermediate
111010 5 5K/12C Intermediate
111020 1 5T/12C Intermediate
111110 6 5J/12C Intermediate
120000 7 5D/5K Slow
120010 5 5C/5K Slow
120011 1 5C/5KA Slow
120020 1 5C/5T Slow
120100 7 5D/5J Slow
120110 8 5C/5J Slow
120200 1 5E/5J Slow
211020 1 5T/12M Intermediate
211110 1 5J/12M Intermediate
220001 1 5K/5KA Slow
220100 4 5J/5K Slow
220110 1 5J/5T Slow
2202–0 1 5J/5J Slow
220200 6 5J/5J Slow
aObserved diplotypes are shown as the number of mutations identified in each individual for each SNP.
0, wild type; 1, heterozygous; 2, homozygous; –, blank. The SNP order is positions 282, 341, 481, 590, 803,
and 857.
TABLE 3 Frequency of NAT2 alleles in the study group
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ters by genotype. Median isoniazid and AcINH time-concentration curves are given in
Fig. 1, right.
For both studies, we calculated the log AcINH concentration/log isoniazid concen-
tration ratio as a measure of acetylation at 2 and 4 h postdose and analyzed this ratio
by genotype (Fig. 2 and 3). In both studies we saw no statistically significant difference
in ratios between genotypes at either 2 or 4 h. In study 2, we again saw increased
variability in this metric among those genotyped as SAs.
Hepatic adverse events. There were no grade 3 and 4 hepatic adverse events in
study 1, and only 1 grade 4 hepatic event was reported from the only participant
with a rapid acetylator genotype in study 2. Although there were more grade 1
hepatic adverse events among the slow acetylator genotype participants than
among the participants with the other genotypes, as shown in Table 9, the
difference was not statistically significant between genotypes (P 0.203 in study 1
and P 0.276 in study 2).
DISCUSSION
We investigated the NAT2 genotype and the PKs of isoniazid and AcINH in black
Zulu South Africans living with HIV from Durban and surrounding areas. We found that
most individuals were of the SA (52.5%) or IA (35.8%) genotype, with only a small
number being of the RA genotype (11.7%). The proportions of the deduced acetylator
phenotypes in our population were broadly similar to those in other African and
Caucasian populations (36, 43, 49, 50) but differed from those previously reported from
within other black ethnic groups within southern Africa. For example, Werely found
that IA genotypes dominated in the Xhosa cohort, with individuals of the SA genotype
comprising only 30% of the cohort (45). Our results were comparable to those of a
recent study by Naidoo et al. in patients from the same geographic area, who reported
34% SAs, 43% IAs, and 18% RAs (51).
There was a high prevalence of the NAT2*5 allelic group, accounting for the slow
acetylator genotype, in our population. In well-studied Caucasian and Asian popula-
tions, four variants, NAT2*4 (wild type, rapid acetylators) and NAT2*5B, NAT2*6A, and
TABLE 4 Frequency of NAT2 haplotypes














TABLE 5 Frequency distribution of NAT2 genotypes and deduced phenotype in the study
group
Genotype No. of participants % of participants Acetylator status
NAT2*4/*11 1 0.8 Rapid
NAT2*12/*12 11 9.2 Rapid
NAT2*11/*12 2 1.7 Rapid
NAT2*5/*12 43 35.8 Intermediate
NAT2*5/*5 63 52.5 Slow
Total 120 100
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NAT2*7B (all slow acetylators), accounted for most NAT2 alleles. In Asian populations,
there are generally a higher proportion of wild-type NAT2*4 alleles and few NAT2*5B
alleles, and this difference largely accounts for the much lower prevalence of RAs in
non-Asian populations. Consistent with other studies in sub-Saharan African popula-
tions, the wild-type NAT*4 allele was far less prevalent and variant alleles were far more
diverse in our study. In our population, the NAT2*5B allele was relatively rare in
comparison to its occurrence in two studies in the black population from the Western
Cape and North West Provinces in South Africa (45, 52). However, in contrast to these
South African populations, there were a diversity of other NAT2*5 alleles, including a
much higher prevalence of the rare NAT2*5J allele (17.5%) and the poorly characterized
NAT2*5K allele (10.4%). The NAT2*6A and NAT2*7B alleles, common in Caucasian and
Asian populations, were not seen in our cohort. In Caucasian and Asian populations,
rapid acetylator NAT2*12 alleles are rarely seen, whereas in populations in sub-Saharan
Africa, the NAT2*12A allele is reported at much higher frequencies (35). In our study, the
NAT2*12A allele did indeed comprise 5.8% of alleles seen, but we saw a much higher
frequency of the NAT2*12C allele (21.2%), in contrast to its frequency in other southern
African cohorts (10, 45, 52, 53).
The isoniazid Cmax and AUC0–∞ demonstrated considerable variability between
individuals in both studies, and almost all participants in study 1 and almost half of the
participants in study 2 had a Cmax below the lower limit of the target range (48). Low
isoniazid concentrations during anti-TB treatment are concerning because it has been
postulated that they may lead to poorer treatment outcomes or the generation of
isoniazid resistance, the likely first step in the evolution of multidrug-resistant TB (MDR
TB). However, the evidence for either of these concerns is mixed, and in this setting, the
prevalence of INH monoresistance is relatively low.
There was a marked difference in PK measures between the two studies analyzed,
with study 1 having much lower measures than study 2. There are several reasons that
could have contributed to this difference. The difference in isoniazid dosing could
explain the lower PK measures, where study 1 used the fixed-dose combination (FDC)
dosing per World Health Organization (WHO)-recommended weight bands, leading to
almost half the participants receiving doses of300 mg, as previously reported (54). All
TABLE 6 Overall isoniazid and N-acetyl-isoniazid PKa
Parameter
Value from:
Study 1 (n 58) Study 2 (n 34)
Isoniazid N-Acetyl-isoniazid Isoniazid N-Acetyl-isoniazid
AUC0–∞ (g·h/ml) 5.53 (3.63–9.12) 5.49 (3.18–9.26) 10.76 (8.24–28.96) 27.67 (23.20–34.67)
Cmax (g/ml) 1.47 (1.14–1.85) 0.90 (0.46–1.40) 3.14 (2.39–4.34) 2.91 (1.73–3.70)
Tmax (h) 1 (1–2) 4 (2–6) 2 (2–2) 3 (3–4)
CL/F (liters/h) 47.64 (35.36–74.11) NA 27.34 (10.83–32.00) NA
t1/2 (h) 2.27 (1.69–3.56) 4.28 (3.29–5.79) 2.62 (2.26–4.07) 5.89 (5.04–8.21)
aAll values are medians (interquartile ranges). AUC0–∞, area under the concentration-time curve from 0 h to infinity; Cmax, maximum concentration; Tmax, time to
maximum concentration; CL/F, clearance; t1/2, elimination half-life; NA, not applicable.
TABLE 7 Study 1 PK parameters by genotypea
Parameter




(n 12) Rapid (n 13) Slow (n 33)
Intermediate
(n 12) Rapid (n 13)
AUC0–∞ (g·h/ml) 5.34 (3.44–7.93) 6.04 (4.27–7.53) 7.56 (5.99–9.60) 5.71 (4.19–11.01) 7.34 (3.15–10.9) 2.81 (0.55–5.06)
Cmax (g/ml) 1.47 (0.97–1.89) 1.54 (1.25–1.76) 1.42 (1.20–2.05) 0.94 (0.63–1.68) 1.07 (0.49–1.70) 0.38 (0.09–0.90)
Tmax (h) 1 (1–2) 1 (1–2) 2 (2–2) 4 (2–4) 4 (4–7) 6 (4–6)
CL/F (liters/h) 57.05 (37.84–103.56) 43.53 (32.05–64.33) 37.75 (31.27–47.92) NA NA NA
t1/2 (h) 1.87 (1.52–3.07) 2.27 (1.78–3.6) 4.00 (2.98–4.73) 4.36 (3.43–5.25) 4.09 (3.13–5.49) 5.42 (3.58–7.48)
aData are for 58 participants. All values are medians (interquartile ranges). AUC0–∞, area under the concentration-time curve from 0 h to infinity; Cmax, maximum
concentration; Tmax, time to maximum concentration; CL/F, clearance; t1/2, elimination half-life; NA, not applicable.
Mthiyane et al. Antimicrobial Agents and Chemotherapy
April 2020 Volume 64 Issue 4 e02376-19 aac.asm.org 6
participants in study 2 received 300-mg doses of isoniazid irrespective of weight.
Although the samples from study 1 did not appear to deteriorate during the 5 years
between the first analysis and subsequent analyses for this study, the possibility of
differences in processing and storage between the studies cannot be excluded. Figure
3 shows the PK measures for INH and AcINH at different time points. Based on those
findings, the acetylator phenotype of the study participants was generally more
intermediate/rapid than what the predominant slow genotype suggests, which is in
contrast to other studies reporting that HIV-infected patients have a tendency toward
a slow acetylator phenotype (55).
We identified no statistically significant difference by NAT2 genotype in a variety of
PK measures; hence, in this cohort we found a poor correlation between the NAT2
genotype and the phenotypic acetylation of isoniazid. Previous studies in other pop-
ulations have shown a good correlation between the NAT2 genotype and isoniazid PK,
suggesting that NAT2 genotyping could be used as a parsimonious way to risk stratify
patients and personalize the dosing of isoniazid in an attempt to maximize efficacy
while minimizing toxicity. There are significant practical difficulties to implementing
these approaches in this setting, but our data suggest that in this population, NAT2
genotyping will not be helpful in guiding anti-TB therapy. A lack of concordance
between genotypic and phenotypic measures of INH acetylation has previously been
reported in HIV-positive cohorts (56, 57). It is likely that in this cohort, as in others, other,
nongenetic factors are more important than or as important as the NAT2 genotype.
Jones et al. found that infection with HIV or the stage of HIV infection may alter phase
I and II drug-metabolizing enzyme (DME) activity in their study of 17 HIV-infected
participants at different levels of immunosuppression (58). They found that HIV infec-
tion was related to an increase in the variability of these DMEs. While additional
pathways, aside from NAT2 genotype, have been implicated in the hepatotoxicity of
isoniazid-containing anti-TB treatment regimens, it is not clear that these pathways
FIG 1 (Left) Study 1 median INH and AcINH concentrations over time for INH and AcINH for 58 patients. (Right) Study 2 median INH and AcINH concentrations
over time for INH and AcINH for 34 patients. The shaded areas indicate the IQR.
TABLE 8 Study 2 PK parameters by genotypea
Parameter
Value for participants with the indicated acetylator phenotype receiving:
Isoniazid N-Acetyl-isoniazid
Slow (n 22) Intermediate (n 11) Rapid (n 1) Slow (n 22) Intermediate (n 11) Rapid (n 1)
AUC0–∞ (g·h/ml) 10.76 (9.73–31.21) 9.09 (7.3–18.75) 26.99 26.04 (22.99–32.76) 6.28 (5.25–10.01) 28.53
Cmax (g/ml) 3.47 (2.49–4.49) 2.96 (2.33–4.02) 3.94 2.85 (1.52–3.68) 3.28 (2.53–4.01) 1.91
Tmax (h) 2 (2–2) 2 (2–2) 2 3 (3–4) 3 (3–3) 4
CL/F (liters/h) 27.87 (9.66–30.83) 33.33 (16.01–41.17) 11.12 NA NA NA
t1/2 (h) 2.64 (2.26–4.08) 2.38 (2.16–2.58) 5.26 5.81 (4.9–7.25) 6.28 (5.25–10.01) 10.97
aData are for 34 participants. All values are medians (interquartile ranges). AUC0–∞, area under the concentration-time curve from 0 h to infinity; Cmax, maximum
concentration; Tmax, time to maximum concentration; CL/F, clearance; t1/2, elimination half-life; NA, not applicable.
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alter isoniazid PK and thus could account for the lack of genotypic and phenotypic
concordance in this study.
Although there were more hepatic adverse events among the SAs, there was no
statistically significant association between genotype and hepatotoxicity in the two
studies, with only 1 patient who was an RA having a grade 4 hepatic adverse event and
2 others who were IAs having grade 3 hepatic adverse events.
In our study, the participants received pyridoxine and co-trimoxazole with the
antituberculosis therapy (ATT) in study 2 but not in study 1, as we used the samples
collected on day 1 for this analysis when only ATT was given. As both INH and
sulfamethoxazole are inhibitors of CYP2C9, this could be one of the reasons for the
variations noted. INH also inhibits CYP3A4, which is induced by rifampin, but this
interaction has not proven significant except when it relates to hepatotoxicity (59, 60).
That the combination of INH and rifampin leads to an increased risk of hepatotoxicity
has been reported in other studies. In our study 2, isoniazid was given with rifabutin,
which is a less potent hepatic enzyme inducer than rifampin, which therefore should
have less interaction with INH (61). Considering the limited effect on hepatotoxicity, the
effect of CYP2E1 was not evident in our study. We cannot confirm or exclude the
possibility of an effect of these CYP450 enzymes on INH metabolism in these partici-
pants.
In our study, the samples were stored at 80°C and the loss of compound due to
storage would have been minimal (62), although studies have not reported on the
results for plasma samples stored longer than 5 weeks, nor have they reported on
sample integrity for the metabolite, AcINH.
Conclusion. Among black Zulu TB-HIV-coinfected South African patients, most had
a slow or intermediate acetylator NAT2 genotype. There was a diversity of specific NAT2
alleles, with the pattern differing from that in previously studied cohorts in other
settings. Despite the rarity of rapid acetylator genotypes, INH PK were variable, and a
FIG 2 Box plots for study 1, representing the medians (solid lines), interquartile ranges (boxes), and ranges (whiskers) for the pharmacokinetic parameters log
maximum concentration (Cmax), log area under the concentration-time curve from 0 h to infinity (AUC0–∞), and half-life for isoniazid (INH) and N-acetyl-isoniazid
(AcINH) stratified by acetylator status and log AcINH concentration to log INH concentration ratio at 2 and 4 h stratified by acetylator genotype. R, I, and S, rapid,
intermediate, and slow acetylator genotypes, respectively.
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substantial proportion of individuals failed to attain minimum efficacy targets. Impor-
tantly, the NAT2 genotype did not explain the PK variability in this cohort or the low
Cmax, which suggests that other factors could be influencing isoniazid bioavailability
and metabolism, and these require further elucidation.
MATERIALS AND METHODS
Participants, study treatment, and sample collection. Participants from two unrelated PK studies
were included (54, 63). Both studies recruited black, Zulu-speaking adults living with HIV from KwaZulu-
Natal, South Africa, between March 2007 and April 2010. Study 1 was entitled “Bioavailability of the Fixed
Dose Formulation Rifafour Containing Isoniazid, Rifampin Pyrazinamide, Ethambutol and the WHO
Recommended First Line Anti-Retroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New
TB Patients at Different Levels of Immunosuppression.” The results of this study have been previously
reported (54). As shown in Table 10, for the purposes of this analysis, we used samples collected on day
1 of the study after an overnight fast, at predose, at 1, 2, 4, 5, 6, 8, and 12 h postdose, with the samples
being analyzed for INH and AcINH for 60 participants with microbiologically proven pulmonary TB (by a
positive sputum culture or smear) who received a standard first-line TB regimen consisting of an FDC, as
described above. The INH dose was 150 mg, 225 mg, 300 mg, and 375 mg per day for participants with
FIG 3 Box plots for study 2, representing the medians (solid lines), interquartile ranges (boxes), and ranges (whiskers) for the pharmacokinetic parameters log
maximum concentration (Cmax), log area under the concentration-time curve from 0 h to infinity (AUC0–∞), and half-life for isoniazid (INH) and N-acetyl-isoniazid
(AcINH) stratified by acetylator status and log AcINH concentration to log INH concentration ratio at 2 and 4 h stratified by acetylator genotype. R, I, and S, rapid,
intermediate, and slow acetylator genotypes, respectively.
TABLE 9 Participants with any hepatic adverse eventsa
Adverse event grade
No. (%) of participants with the indicated acetylator phenotype
Study 1 Study 2
Rapid Intermediate Slow Total Rapid Intermediate Slow Total
1 7 9 25 41 0 5 10 15
2 2 0 0 2 0 1 1 2
3 0 0 0 0 0 2 1 3
4 0 0 0 0 1 0 0 1
Total 9 (20.9) 9 (20.9) 25 (61) 43 (100) 1 (4.8) 8 (30.1) 12 (57.1) 21 (100)
aHepatic adverse events from the two studies included a combination of elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP), gamma-glutamyltransferase, and total bilirubin levels.
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weights of 30 to 37 kg, 38 to 54 kg, 55 to 70 kg, and 70 kg and above, respectively, per WHO guidelines
(64). Blood from each participant was collected in a PAXgene tube for NAT2 genotyping. In addition,
genotyping was performed on a further 20 participants without TB who were recruited to this study (54).
Study 2, entitled “Pharmacokinetics of Rifabutin Combined with Antiretroviral Therapy in the
Treatment of Tuberculosis Patients with HIV Infection in South Africa,” was a randomized controlled trial
of two different rifabutin doses coadministered with lopinavir-ritonavir-based antiretroviral therapy (63,
65). The participants initially received 6 weeks of standard intensive-phase treatment, followed by
2 weeks with rifabutin at 300 mg daily, which replaced rifampin. After 2 weeks of the continuation phase,
during which the participants received only isoniazid and rifabutin (both at 300 mg daily), PK sampling
was carried out. Individuals were fasted overnight, and a standard hospital breakfast was served 2 h after
drug ingestion. Sampling was conducted predose and at 2, 3, 4, 5, 6, 8, 12, and 24 h after drug intake,
with samples being analyzed for isoniazid and AcINH for 40 participants. NAT2 genotyping was per-
formed on 40 participants, with 34 participants having both PK sampling and genotyping.
All participants receiving anti-TB treatment in both studies were given pyridoxine for peripheral
neuropathy prophylaxis, and patients with CD4 counts below 200 cells/mm3 received co-trimoxazole. No
participants were on antiretrovirals at the time of PK sampling. Both studies were approved by the South
African Medicines Control Council (SAMCC), Biomedical Research Ethics Committee (BREC), of the
University of KwaZulu-Natal (study 1, approval number E294/05; study 2, approval number BFC011/07)
and the South African Medical Research Council (SAMRC) Ethics Committee. Study 1 was also approved
by the WHO Ethics Research Ethics Committee. Written informed consent was obtained from all
participants.
NAT2 genotyping procedures. Total genomic DNA was isolated from whole blood using a QIAamp
DNA minikit (Qiagen, Crawly, UK) according to the manufacturer’s instructions. Participants were
genotyped, using a DNA Engine Chromo4 system (Bio-Rad Laboratories, Hercules, CA) and Opticon
Monitor (v.3.1) software (Bio-Rad Laboratories), for 6 NAT2 SNPs, 282CT, 341TC, 481CT, 857GA,
590GA, and 803AG, using Life Technologies prevalidated probe-based TaqMan assays per the
manufacturer’s instructions (Life Technologies, Paisley, UK). Each participant sample was analyzed in
duplicate.
Haplotype assignment and acetylator genotype inference. Haplotype assignment from probe-
based SNP data is poorly described in African populations. We elected to employ an unbiased Phase
analysis, which takes the data set as a whole to assign the most likely haplotype for each individual,
alongside a probability for this assignment (66, 67). The haplotype for each individual and the acetylator
genotype for each haplotype were defined per the guidelines of the NAT Gene Nomenclature Committee
(http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm). Individuals with two rapid acetylator al-
leles were defined as RAs, those with two slow acetylator alleles were defined as SAs, and those with one
fast acetylator allele and one slow acetylator allele were defined as IAs.
Isoniazid and N-acetyl-isoniazid PK and phenotype inference. Blood samples were collected and
immediately placed on ice, before centrifugation within 60 min, immediate separation, and storage of
plasma at 70°C until analysis. The concentrations of isoniazid, AcINH, and the 6-aminonicotinic acid
internal control were quantified using validated high-performance liquid chromatography and tandem
mass spectrometry (HPLC-MS/MS). Sample preparation included a protein precipitation step with ace-
tonitrile and subsequent dilution with water. The analytes were chromatographically separated using a
Waters Exterra C18 column (particle size, 3.5 m; 50 mm by 2.1 mm) and detected using an AB Sciex 5500
Q-Trap mass spectrometer. All analytes were analyzed isocratically with an acetonitrile–water–0.1%
formic acid mobile phase. Isoniazid, AcINH, and the internal standard were analyzed at mass transitions
of the precursor ions (m/z) of 137.9, 180.1, and 138.7 to the product ions (m/z) of 66.0, 78.6, and 50.9,
respectively. Chromatographic data acquisition, peak integration, and quantification of analytes were
performed using Analyst software (version 1.5.2). We constructed time-concentration curves in the PK
package in R for Windows (version 3.5.1). We characterized the isoniazid and AcINH PK parameters
maximum concentration (Cmax), time to maximum concentration (Tmax), area under the concentration-
time curve from 0 h to infinity (AUC0–∞), apparent oral clearance (CL), and elimination half-life and
compared Cmax to published efficacy targets (48). AUC0–∞ was calculated using the trapezoid rule,
apparent oral clearance was estimated by dose/AUC0–∞, and the elimination half-life was estimated by
TABLE 10 PK time points and dosinga
Study
Schedule of PK sampling (day of anti-TB
treatment) Treatment
Study 1 Day 1, with sampling predose and at 1, 2, 4, 6, 8,
and 12 h after the dose
Four-drug FDC formulation (EMB, RMP, INH, and PZA at 275, 150, 75,
and 400 mg, respectively) dosed daily by weight bandb
Study 2 Enrollment at wk 6 and standard weight band-based treatment with
RMP, INH, PZA, and EMB (as in study 1)
At wk 6 and 7, RMP was replaced with RFB at 300 mg daily
Day 63 (after 2 wk on continuation phase RBN-
INH) with sampling predose and 2, 3, 4, 5, 6, 8,
12, and 24 h after the dose
At wk 8 and 9, RFB at 300 mg and INH at 300 mg
aPK, pharmacokinetics; RMP, rifampin; PZA, pyrazinamide; EMB, ethambutol; FDC, fixed-dose combination; RFB, rifabutin (Mycobutin, Pfizer).
bParticipants weighing 30 to 37 kg received 2 tablets, those weighing 38 to 54 kg received 3 tablets, those weighing 55 to 70 kg received 4 tablets, and those
weighing 70 kg received 5 tablets.
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regression analysis of the log concentrations of the terminal exponent of elimination. We analyzed the
ratio of log AcINH concentration/log isoniazid concentration at 2 and 4 h to assess the acetylation
phenotype.
Sample processing and HPLC-MS were initially conducted in 2010 for study 1. Samples remained in
storage and were later moved to a new storage facility before they were shipped to a different laboratory
for determination of isoniazid and AcINH concentrations as described above (having previously only had
isoniazid concentrations determined). To confirm the integrity of these samples, we compared the
isoniazid AUC0–∞ from the current analysis with that previously reported for the same samples analyzed
in 2010.
Statistical methods. All data were entered into EpiData software and transferred to either Stata
(version 14) or R for Windows (version 3.5.1) for statistical analysis. Demographic characteristics were
presented as frequencies and percentages for categorical variables and as means with standard devia-
tions for continuous variables. Descriptive PK data were described as the median and interquartile
ranges. Cmax and AUC0–∞ were log transformed prior to comparison between genotypes. PK parameters
were compared, by genotype, using the Wilcoxon rank-sum test or the Kruskal-Wallis test.
Hepatic adverse events. Hepatic adverse events were defined as elevated alanine transaminase
(ALT) and aspartate transaminase (AST) levels, elevated alkaline phosphatase levels, and elevated total
bilirubin levels, graded per the Division of AIDS, NIAID, NIH, toxicity table for grading the severity of
HIV-positive adult adverse events.
Data availability. Data related to this study have been deposited at https://figshare.com/s/
8b42c433e1edce625849.
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